Tag: hemophilia b gene therapy industry analysis

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Hemophilia B Gene Therapy Market Size Forecast: How Large Could The Market Become By 2030?

The hemophilia b gene therapy market has experienced considerable expansion in recent years. It is anticipated to grow from $0.55 billion in 2025 to $0.71 billion in 2026, at a compound annual growth rate (CAGR) of 29.6%. This past growth can be attributed to several factors including advances in gene delivery technologies, improved understanding of hemophilia b genetics, the broadening of clinical research programs, the escalating burden of lifelong replacement therapy, and the establishment of specialized treatment centers.

The hemophilia b gene therapy market size is projected to experience substantial growth in the coming years, with expectations to reach $2.01 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 29.8%. This expansion during the forecast period is attributed to increasing approvals of gene therapies, rising investments in rare disease treatments, a growing demand for durable therapeutic outcomes, the expansion of advanced manufacturing capabilities, and an increase in patient access programs. Major trends anticipated in this period include enhanced progress in one-time curative therapies, a greater focus on long-term factor IX expression, continuous optimization of AAV vector design, the expansion of personalized gene therapy approaches, and improved regulatory alignment for advanced therapies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33162&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Jul_PR

Hemophilia B Gene Therapy Market Demand Drivers: What Is Fueling Industry Growth?

The growing volume of gene therapy clinical trials is anticipated to boost the expansion of the hemophilia B gene therapy market in the future. These trials are investigative studies aimed at assessing the safety, effectiveness, and lasting therapeutic promise of gene-based treatments in human subjects. The surge in gene therapy clinical trials stems from increased capital inflow from biopharmaceutical firms, progress in viral vector technology, supportive regulatory environments, and the imperative to tackle rare genetic conditions with significant unmet medical demands, such as hemophilia B. Hemophilia B gene therapy gains advantages from this expanding field of clinical trials by utilizing existing clinical development routes, regulatory know-how, and production capabilities linked to in vivo gene delivery methods. For instance, in January 2026, according to Bioindustry Association (BIA) a UK-based national trade association, UK recorded 193 ongoing advanced therapy clinical trials, broadly similar to 2024, with over half in early stages, around 80% commercially sponsored, and more than 80% focused on gene therapies, evenly split between ex vivo and in vivo approaches. Consequently, the increasing number of cell and gene therapy clinical trials is stimulating growth in the hemophilia B gene therapy market.

Hemophilia B Gene Therapy Market Segment Breakdown: Which Categories Generate The Most Revenue?

The hemophilia b gene therapy market covered in this report is segmented –

1) By Therapy: Adeno-Associated Viral (AAV) Vectors; Lentiviral Vectors; Retroviral Vectors

2) By Disease Severity: Severe Hemophilia B; Moderate Hemophilia B; Mild Hemophilia B

3) By Treatment Type: On-Demand; Cure; Prophylaxis

4) By Patient Age Group: Geriatric; Adults; Pediatric

5) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies

Subsegments:

1) By Adeno-Associated Viral Vectors: Single-Stranded Adeno-Associated Viral Vectors; Self-Complementary Adeno-Associated Viral Vectors; Tissue Specific Promoter Adeno-Associated Viral Vectors; Capsid Modified Adeno-Associated Viral Vectors

2) By Lentiviral Vectors: Integrating Lentiviral Vectors; Non-Integrating Lentiviral Vectors; Self-Inactivating Lentiviral Vectors; Pseudotyped Lentiviral Vectors

3) By Retroviral Vectors: Gamma Retroviral Vectors; Alpha Retroviral Vectors; Moloney Murine Leukemia Virus Retroviral Vectors; Spumaretroviral Vectors

Hemophilia B Gene Therapy Market Innovation Trends: Which Developments Are Transforming The Industry?

Leading companies in the hemophilia B gene therapy market are increasingly prioritizing innovations in advanced gene delivery platforms, particularly optimized adeno-associated virus (AAV)–based vector systems, to enhance treatment effectiveness and patient safety. These refined AAV-based vector systems function as sophisticated viral delivery mechanisms, enabling the efficient and controlled transfer of functional clotting factor IX genes into target hepatocytes, thereby supporting long-term endogenous factor production. For instance, in May 2023, CSL Behring GmbH, a Germany-based biotechnology company, obtained European Commission approval for HEMGENIX, which is the first gene therapy authorized for the treatment of hemophilia B. HEMGENIX is prescribed for adult patients with severe or moderate hemophilia B who do not have a history of factor IX inhibitors and is designed to reduce or eliminate the requirement for routine factor IX prophylaxis. Results from the pivotal HOPE-B clinical study showed that a significant number of treated patients no longer needed regular factor IX infusions, demonstrating a sustained therapeutic benefit and emphasizing the potential of next-generation AAV-based gene therapies in long-term disease management.

Hemophilia B Gene Therapy Market Key Players And Strategic Industry Positioning

Major companies operating in the hemophilia b gene therapy market are REGENXBIO Inc., Pfizer Inc., Bayer Aktiengesellschaft (Bayer AG), Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring LLC, Lonza Group AG, Alnylam Pharmaceuticals Inc., GenScript ProBio LLC, Ultragenyx Pharmaceutical Inc., Takara Bio Inc., Sangamo Therapeutics Inc., Precision BioSciences Inc., Synthego Corporation, MaxCyte Inc., uniQure N.V., Freeline Therapeutics Ltd., Be Biopharma Inc., Asklepios BioPharmaceutical Inc., Cellectis S.A.

Access The Complete Hemophilia B Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/hemophilia-b-gene-therapy-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Jul_PR

Hemophilia B Gene Therapy Market Regional Outlook: Where Are The Largest Opportunities Located?

North America was the largest region in the hemophilia b gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemophilia b gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Much Larger Will The Hemophilia B Gene Therapy Market Become By 2030 Compared To 2026?

The hemophilia b gene therapy market size has seen significant expansion in recent years. It is anticipated to increase from $0.55 billion in 2025 to $0.71 billion in 2026, achieving a compound annual growth rate (CAGR) of 29.6%. The historical growth can be linked to several factors, including advancements in gene delivery technologies, a deeper understanding of hemophilia b genetics, the expansion of clinical research programs, the increasing burden associated with lifelong replacement therapy, and the presence of specialized treatment centers.

The hemophilia b gene therapy market size is projected to experience substantial growth over the upcoming years. It is forecast to achieve a valuation of **$2.01 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 29.8%**. This expansion during the forecast period is primarily driven by factors such as the increasing approvals of gene therapies, rising investments in treatments for rare diseases, a growing demand for enduring therapeutic results, the enhancement of advanced manufacturing capabilities, and an increase in patient access programs. Furthermore, significant trends anticipated during this period include continued progress in one-time curative therapies, a heightened focus on long-term factor IX expression, ongoing optimization of AAV vector design, the expansion of personalized gene therapy approaches, and improved regulatory harmonization for advanced therapies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33162&type=smp

What Influential Factors Are Boosting The Hemophilia B Gene Therapy Market Demand?

The hemophilia B gene therapy market is projected to expand due to the increasing volume of gene therapy clinical trials. These trials are research endeavors aimed at assessing the safety, effectiveness, and lasting therapeutic impact of gene-based treatments in human subjects. The growth in gene therapy clinical trials is spurred by greater investment from biopharmaceutical firms, advancements in viral vector technologies, supportive regulatory environments, and the critical need to address rare genetic conditions with significant unmet medical requirements, including hemophilia B. This expanding landscape of clinical trials benefits hemophilia B gene therapy by providing established clinical development routes, regulatory expertise, and manufacturing capabilities pertinent to in vivo gene delivery methods. For example, in January 2026, the Bioindustry Association (BIA), a national trade association based in the UK, reported 193 ongoing advanced therapy clinical trials in the UK, a figure broadly comparable to 2024. Over half of these trials were in early stages, approximately 80% were commercially sponsored, and more than 80% focused on gene therapies, divided equally between ex vivo and in vivo approaches. Consequently, the escalation in cell and gene therapy clinical trials is propelling the hemophilia B gene therapy market’s expansion. Rising Adoption Of Personalized Medicine Is Fueling The Growth Of The Market Due To Its Role In Enabling Tailored Treatments, Patient Stratification, And Improved Therapeutic Outcomes

What Are The Core Segment Classifications In The Hemophilia B Gene Therapy Market?

The hemophilia b gene therapy market covered in this report is segmented –

1) By Therapy: Adeno-Associated Viral (AAV) Vectors; Lentiviral Vectors; Retroviral Vectors

2) By Disease Severity: Severe Hemophilia B; Moderate Hemophilia B; Mild Hemophilia B

3) By Treatment Type: On-Demand; Cure; Prophylaxis

4) By Patient Age Group: Geriatric; Adults; Pediatric

5) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies

Subsegments:

1) By Adeno-Associated Viral Vectors: Single-Stranded Adeno-Associated Viral Vectors; Self-Complementary Adeno-Associated Viral Vectors; Tissue Specific Promoter Adeno-Associated Viral Vectors; Capsid Modified Adeno-Associated Viral Vectors

2) By Lentiviral Vectors: Integrating Lentiviral Vectors; Non-Integrating Lentiviral Vectors; Self-Inactivating Lentiviral Vectors; Pseudotyped Lentiviral Vectors

3) By Retroviral Vectors: Gamma Retroviral Vectors; Alpha Retroviral Vectors; Moloney Murine Leukemia Virus Retroviral Vectors; Spumaretroviral Vectors

Which Trends Are Contributing To Changes In The Hemophilia B Gene Therapy Market?

Companies operating in the hemophilia B gene therapy market are increasingly concentrating on advancements in next-generation gene delivery platforms, particularly optimized adeno-associated virus (AAV)–based vector systems, to enhance therapeutic efficacy and safety. These optimized AAV-based vector systems function as advanced viral delivery platforms, enabling the efficient and controlled transfer of functional clotting factor IX genes into target hepatocytes, which supports long-term endogenous factor production. For example, in May 2023, CSL Behring GmbH, a Germany-based biotechnology company, obtained European Commission approval for HEMGENIX, the initial gene therapy sanctioned for treating hemophilia B. HEMGENIX is prescribed for adult patients with severe or moderate hemophilia B who have no history of factor IX inhibitors, with the goal of reducing or eliminating the need for routine factor IX prophylaxis. Results from the pivotal HOPE-B clinical study showed that a substantial number of treated patients no longer required regular factor IX infusions, demonstrating sustained therapeutic benefit and underscoring the potential of next-generation AAV-based gene therapies in managing the disease long-term.

Who Are The Firms Contributing To The Hemophilia B Gene Therapy Market Ecosystem?

Major companies operating in the hemophilia b gene therapy market are REGENXBIO Inc., Pfizer Inc., Bayer Aktiengesellschaft (Bayer AG), Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring LLC, Lonza Group AG, Alnylam Pharmaceuticals Inc., GenScript ProBio LLC, Ultragenyx Pharmaceutical Inc., Takara Bio Inc., Sangamo Therapeutics Inc., Precision BioSciences Inc., Synthego Corporation, MaxCyte Inc., uniQure N.V., Freeline Therapeutics Ltd., Be Biopharma Inc., Asklepios BioPharmaceutical Inc., Cellectis S.A.

Access The Complete Hemophilia B Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/hemophilia-b-gene-therapy-market-report

What Is The Largest Regional Market In The Hemophilia B Gene Therapy Market?

North America was the largest region in the hemophilia b gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemophilia b gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Hemophilia B Gene Therapy Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Hemophilia B Gene Therapy Market In 2026 And 2030?

The hemophilia b gene therapy market has experienced substantial expansion in recent years. Its valuation is projected to rise from $0.55 billion in 2025 to $0.71 billion in 2026, achieving a compound annual growth rate (CAGR) of 29.6%. This historical development can be ascribed to advancements in gene delivery technologies, a greater insight into hemophilia b genetics, the broadening of clinical research programs, the growing impact of lifelong replacement therapy, and the presence of specialized treatment centers.

The market for hemophilia b gene therapy is projected to experience rapid expansion over the upcoming years. This market is anticipated to reach a valuation of $2.01 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 29.8%. Several factors will drive this growth during the projection period, including a rise in gene therapy approvals, increased investments targeting rare disease treatments, a surge in demand for lasting therapeutic effects, the broadening of advanced manufacturing capacities, and the expansion of patient access initiatives. Key trends anticipated within this forecast timeframe encompass significant strides in single-dose curative treatments, an intensifying emphasis on sustained factor ix expression, the ongoing refinement of AAV vector designs, the broadening scope of personalized gene therapy methods, and improved regulatory harmonization for cutting-edge therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33162&type=smp

What Major Factors Are Driving The Hemophilia B Gene Therapy Market Forward?

The growing number of gene therapy clinical trials is anticipated to drive the expansion of the hemophilia B gene therapy market. These trials are research studies designed to assess the safety, effectiveness, and long-term treatment potential of gene-based therapies in human participants. The increase in gene therapy clinical trials is fueled by greater investment from biopharmaceutical companies, developments in viral vector technology, supportive regulatory frameworks, and the necessity to address rare genetic disorders with significant unmet medical needs, including hemophilia B. Hemophilia B gene therapy benefits from this expanding landscape by utilizing established clinical development pathways, regulatory expertise, and manufacturing capabilities linked to in vivo gene delivery methods. For example, in January 2026, the Bioindustry Association (BIA) reported that the UK had 193 ongoing advanced therapy clinical trials, similar to 2024, with more than half in early stages, approximately 80% commercially sponsored, and over 80% focused on gene therapies, equally divided between ex vivo and in vivo approaches. Consequently, the increasing cell and gene therapy clinical trials are boosting the growth of the hemophilia B gene therapy market. The increasing embrace of personalized medicine is expected to drive the hemophilia B gene therapy market forward. Personalized medicine is a medical strategy that customizes disease prevention, diagnosis, and treatment based on an individual’s genetic, molecular, or clinical characteristics to enhance therapeutic results and minimize side effects. The growing adoption of personalized medicine is propelled by advances in genomics, better biomarker identification, and increasing regulatory backing for targeted therapies that depart from uniform treatment models. Hemophilia B gene therapy is well-aligned with personalized medicine principles, addressing the root genetic cause of the disease and providing long-term therapeutic advantages through individualized gene-based interventions. These therapies depend on patient-specific genetic and clinical profiling to determine suitability, optimize dosage, and monitor treatment longevity and safety. For instance, in February 2024, the Personalized Medicine Coalition stated that the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023. Therefore, the rising adoption of personalized medicine is fueling the growth of the hemophilia B gene therapy market.

What Segment Categories Shape The Hemophilia B Gene Therapy Market Segment Landscape?

The hemophilia b gene therapy market covered in this report is segmented –

1) By Therapy: Adeno-Associated Viral (AAV) Vectors; Lentiviral Vectors; Retroviral Vectors

2) By Disease Severity: Severe Hemophilia B; Moderate Hemophilia B; Mild Hemophilia B

3) By Treatment Type: On-Demand; Cure; Prophylaxis

4) By Patient Age Group: Geriatric; Adults; Pediatric

5) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies

Subsegments:

1) By Adeno-Associated Viral Vectors: Single-Stranded Adeno-Associated Viral Vectors; Self-Complementary Adeno-Associated Viral Vectors; Tissue Specific Promoter Adeno-Associated Viral Vectors; Capsid Modified Adeno-Associated Viral Vectors

2) By Lentiviral Vectors: Integrating Lentiviral Vectors; Non-Integrating Lentiviral Vectors; Self-Inactivating Lentiviral Vectors; Pseudotyped Lentiviral Vectors

3) By Retroviral Vectors: Gamma Retroviral Vectors; Alpha Retroviral Vectors; Moloney Murine Leukemia Virus Retroviral Vectors; Spumaretroviral Vectors

Which Trends Are Impacting The Progress Of The Hemophilia B Gene Therapy Market?

Leading companies within the hemophilia B gene therapy market are increasingly focusing on advancements in next-generation gene delivery platforms, particularly optimized adeno-associated virus (AAV)–based vector systems, to enhance both therapeutic efficacy and safety. These refined AAV-based vector systems act as sophisticated viral delivery mechanisms, enabling the efficient and controlled transfer of functional clotting factor IX genes into target hepatocytes, which supports long-term endogenous factor production. For instance, in May 2023, CSL Behring GmbH, a biotechnology firm based in Germany, obtained European Commission approval for HEMGENIX, which stands as the inaugural gene therapy sanctioned for managing hemophilia B. HEMGENIX is indicated for adult patients with severe or moderate hemophilia B who do not have a history of factor IX inhibitors, and it aims to reduce or eliminate the necessity for routine factor IX prophylaxis. Findings from the pivotal HOPE-B clinical study revealed that a significant portion of treated patients no longer required regular factor IX infusions, thereby demonstrating sustained therapeutic benefits and highlighting the potential of advanced AAV-based gene therapies in long-term disease management.

Who Are The Companies Operating Across The Hemophilia B Gene Therapy Market Value Chain?

Major companies operating in the hemophilia b gene therapy market are REGENXBIO Inc., Pfizer Inc., Bayer Aktiengesellschaft (Bayer AG), Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring LLC, Lonza Group AG, Alnylam Pharmaceuticals Inc., GenScript ProBio LLC, Ultragenyx Pharmaceutical Inc., Takara Bio Inc., Sangamo Therapeutics Inc., Precision BioSciences Inc., Synthego Corporation, MaxCyte Inc., uniQure N.V., Freeline Therapeutics Ltd., Be Biopharma Inc., Asklepios BioPharmaceutical Inc., Cellectis S.A.

Get The Full Hemophilia B Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/hemophilia-b-gene-therapy-market-report

Which Region Has The Greatest Market Share In The Hemophilia B Gene Therapy Market?

North America was the largest region in the hemophilia b gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemophilia b gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Hemophilia B Gene Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=33162&type=smp

Browse Through More Reports Similar to the Global Hemophilia B Gene Therapy Market 2026, By The Business Research Company

Hepatitis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Acquired Hemophilia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report

Hemophilia Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Hemophilia B Gene Therapy Market During The Forecast Period 2026–2030?

The hemophilia b gene therapy market has experienced rapid expansion in recent years. Projections indicate it will grow from $0.55 billion in 2025 to $0.71 billion in 2026, maintaining a compound annual growth rate (CAGR) of 29.6%. Historically, this growth can be attributed to enhancements in gene delivery technologies, a deeper understanding of hemophilia b genetics, the expansion of clinical research programs, the increasing challenge posed by lifelong replacement therapy, and the availability of specialized treatment centers.

The hemophilia b gene therapy market size is anticipated to experience substantial growth in the upcoming years. It is forecast to expand to $2.01 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 29.8%. This projected expansion during the forecast period is driven by factors such as increasing approvals for gene therapies, growing investments in treatments for rare diseases, a rising demand for enduring therapeutic outcomes, the expansion of advanced manufacturing capabilities, and an increase in patient access programs. Significant trends expected in this period include ongoing progress in one-time curative therapies, a heightened focus on long-term factor IX expression, continuous optimization of AAV vector design, the expansion of personalized gene therapy strategies, and enhanced regulatory alignment for advanced therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33162&type=smp

What Key Drivers Are Influencing The Growth Of The Hemophilia B Gene Therapy Market?

The increasing number of gene therapy clinical trials is anticipated to boost the growth of the hemophilia B gene therapy market in the future. These trials are research studies designed to evaluate the safety, effectiveness, and long-term therapeutic potential of gene-based treatments in human subjects. The increase in gene therapy clinical trials is propelled by greater investment from biopharmaceutical companies, advancements in viral vector technology, supportive regulatory frameworks, and the necessity to address rare genetic disorders with high unmet medical needs, including hemophilia B. Hemophilia B gene therapy benefits from this expanding clinical trial landscape by utilizing established clinical development pathways, regulatory expertise, and manufacturing capabilities associated with in vivo gene delivery methods. For example, in January 2026, the Bioindustry Association (BIA), a UK-based national trade association, reported that the UK had 193 ongoing advanced therapy clinical trials, similar to 2024, with more than half in early stages, approximately 80% commercially sponsored, and over 80% focused on gene therapies, equally divided between ex vivo and in vivo approaches. Consequently, the growing number of cell and gene therapy clinical trials is propelling the hemophilia B gene therapy market’s expansion.

What Market Segments Are Evaluated Within The Hemophilia B Gene Therapy Market?

The hemophilia b gene therapy market covered in this report is segmented –

1) By Therapy: Adeno-Associated Viral (AAV) Vectors; Lentiviral Vectors; Retroviral Vectors

2) By Disease Severity: Severe Hemophilia B; Moderate Hemophilia B; Mild Hemophilia B

3) By Treatment Type: On-Demand; Cure; Prophylaxis

4) By Patient Age Group: Geriatric; Adults; Pediatric

5) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies

Subsegments:

1) By Adeno-Associated Viral Vectors: Single-Stranded Adeno-Associated Viral Vectors; Self-Complementary Adeno-Associated Viral Vectors; Tissue Specific Promoter Adeno-Associated Viral Vectors; Capsid Modified Adeno-Associated Viral Vectors

2) By Lentiviral Vectors: Integrating Lentiviral Vectors; Non-Integrating Lentiviral Vectors; Self-Inactivating Lentiviral Vectors; Pseudotyped Lentiviral Vectors

3) By Retroviral Vectors: Gamma Retroviral Vectors; Alpha Retroviral Vectors; Moloney Murine Leukemia Virus Retroviral Vectors; Spumaretroviral Vectors

What Industry Trends Are Redefining The Hemophilia B Gene Therapy Market?

Leading companies within the hemophilia B gene therapy market are increasingly prioritizing innovations in advanced gene delivery platforms, notably optimized adeno-associated virus (AAV)–based vector systems, to enhance both therapeutic efficacy and patient safety. These optimized AAV-based vector systems serve as sophisticated viral delivery mechanisms that facilitate the efficient and controlled transfer of functional clotting factor IX genes into target hepatocytes, thereby supporting long-term endogenous factor production. For instance, in May 2023, CSL Behring GmbH, a Germany-based biotechnology company, obtained European Commission approval for HEMGENIX, the first gene therapy sanctioned for the treatment of hemophilia B. HEMGENIX is prescribed for adult patients with severe or moderate hemophilia B who do not have a history of factor IX inhibitors and aims to reduce or eliminate the necessity for routine factor IX prophylaxis. Based on results from the pivotal HOPE-B clinical study, a considerable number of treated patients no longer required regular factor IX infusions, showcasing sustained therapeutic benefit and emphasizing the potential of next-generation AAV-based gene therapies in managing the disease long-term.

Which Companies Hold Significant Positions In The Hemophilia B Gene Therapy Market?

Major companies operating in the hemophilia b gene therapy market are REGENXBIO Inc., Pfizer Inc., Bayer Aktiengesellschaft (Bayer AG), Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring LLC, Lonza Group AG, Alnylam Pharmaceuticals Inc., GenScript ProBio LLC, Ultragenyx Pharmaceutical Inc., Takara Bio Inc., Sangamo Therapeutics Inc., Precision BioSciences Inc., Synthego Corporation, MaxCyte Inc., uniQure N.V., Freeline Therapeutics Ltd., Be Biopharma Inc., Asklepios BioPharmaceutical Inc., Cellectis S.A.

Read the full hemophilia b gene therapy market report here:

https://www.thebusinessresearchcompany.com/report/hemophilia-b-gene-therapy-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Hemophilia B Gene Therapy Market?

North America was the largest region in the hemophilia b gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemophilia b gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Hemophilia B Gene Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33162&type=smp

Browse Through More Reports Similar to the Global Hemophilia B Gene Therapy Market 2026, By The Business Research Company

Hepatitis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Acquired Hemophilia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report

Hemophilia Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the hemophilia b gene therapy market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Hemophilia B Gene Therapy Market from 2026 to 2030?

The hemophilia b gene therapy market size has witnessed substantial growth in recent years. It is anticipated to expand from $0.55 billion in 2025 to $0.71 billion in 2026, reflecting a compound annual growth rate (CAGR) of 29.6%. This historical expansion can be attributed to several factors including advancements in gene delivery technologies, a greater comprehension of hemophilia b genetics, the proliferation of clinical research programs, the increasing challenge posed by lifelong replacement therapy, and the availability of specialized treatment centers.

The hemophilia b gene therapy market size is projected to experience substantial growth in the upcoming years. This market is forecast to reach $2.01 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 29.8%. This anticipated growth during the forecast period is driven by several factors, including the increasing number of gene therapy approvals, escalating investments in treatments for rare diseases, a rising need for lasting therapeutic results, the expansion of sophisticated manufacturing capacities, and the growth of patient access initiatives. Key trends anticipated during this period encompass advancements in single-dose curative therapies, a heightened emphasis on sustained Factor IX expression, the continuous refinement of AAV vector designs, the broadening of personalized gene therapy strategies, and improved regulatory harmonization for advanced therapeutic interventions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33162&type=smp

What Drivers Are Affecting Demand In The Hemophilia B Gene Therapy Market?

The hemophilia B gene therapy market is projected to expand due to the increasing number of gene therapy clinical trials. These research studies evaluate the safety, effectiveness, and long-term potential of gene-based treatments in humans. The growth in such trials is fueled by greater investment from biopharmaceutical firms, developments in viral vector technology, supportive regulations, and the necessity to address rare genetic conditions with significant unmet medical needs, including hemophilia B. Hemophilia B gene therapy benefits from this expanding landscape by utilizing existing clinical development pathways, regulatory expertise, and manufacturing capabilities linked with in vivo gene delivery methods. For example, in January 2026, the Bioindustry Association (BIA), a UK national trade association, reported 193 ongoing advanced therapy clinical trials in the UK, similar to 2024. Over half were in early stages, approximately 80% were commercially sponsored, and more than 80% concentrated on gene therapies, split equally between ex vivo and in vivo approaches. Consequently, the increasing number of cell and gene therapy clinical trials is stimulating the growth of the hemophilia B gene therapy market. The market’s growth is being driven by the increasing integration of personalized medicine, which facilitates customized treatments, patient categorization, and enhanced therapeutic results. The hemophilia B gene therapy market is anticipated to grow with the increasing adoption of personalized medicine. This medical strategy customizes disease prevention, diagnosis, and treatment based on an individual’s genetic, molecular, or clinical features to improve treatment outcomes and minimize adverse reactions. The greater use of personalized medicine is propelled by advances in genomics, better biomarker identification, and increasing regulatory backing for targeted therapies that move away from universal treatment models. Hemophilia B gene therapy aligns well with personalized medicine principles by addressing the genetic root cause of the condition and providing sustained therapeutic benefits through individualized gene-based interventions. These therapies depend on patient-specific genetic and clinical profiles to determine suitability, refine dosing, and track treatment longevity and safety. For instance, in February 2024, the Personalized Medicine Coalition, a US nonprofit organization, noted that the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023. Therefore, the growing adoption of personalized medicine is a key factor driving the expansion of the hemophilia B gene therapy market.

Which Segment Groups Are Influencing The Hemophilia B Gene Therapy Market?

The hemophilia b gene therapy market covered in this report is segmented –

1) By Therapy: Adeno-Associated Viral (AAV) Vectors; Lentiviral Vectors; Retroviral Vectors

2) By Disease Severity: Severe Hemophilia B; Moderate Hemophilia B; Mild Hemophilia B

3) By Treatment Type: On-Demand; Cure; Prophylaxis

4) By Patient Age Group: Geriatric; Adults; Pediatric

5) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies

Subsegments:

1) By Adeno-Associated Viral Vectors: Single-Stranded Adeno-Associated Viral Vectors; Self-Complementary Adeno-Associated Viral Vectors; Tissue Specific Promoter Adeno-Associated Viral Vectors; Capsid Modified Adeno-Associated Viral Vectors

2) By Lentiviral Vectors: Integrating Lentiviral Vectors; Non-Integrating Lentiviral Vectors; Self-Inactivating Lentiviral Vectors; Pseudotyped Lentiviral Vectors

3) By Retroviral Vectors: Gamma Retroviral Vectors; Alpha Retroviral Vectors; Moloney Murine Leukemia Virus Retroviral Vectors; Spumaretroviral Vectors

How Are Emerging Trends Affecting The Progression Of The Hemophilia B Gene Therapy Market?

Leading companies active in the hemophilia B gene therapy market are increasingly concentrating on breakthroughs in advanced gene delivery platforms, specifically optimized adeno-associated virus (AAV)–based vector systems, to improve treatment effectiveness and safety. These optimized AAV-based vector systems function as sophisticated viral delivery platforms, enabling the efficient and controlled transfer of functional clotting factor IX genes into target hepatocytes, thereby supporting long-term endogenous factor production. For instance, in May 2023, CSL Behring GmbH, a Germany-based biotechnology company, secured European Commission approval for HEMGENIX, marking it as the first gene therapy sanctioned for the treatment of hemophilia B. HEMGENIX is indicated for adult patients with severe or moderate hemophilia B without a history of factor IX inhibitors and is designed to lessen or eliminate the requirement for routine factor IX prophylaxis. Based on findings from the pivotal HOPE-B clinical study, a significant percentage of treated patients no longer needed regular factor IX infusions, demonstrating enduring therapeutic benefits and emphasizing the potential of next-generation AAV-based gene therapies in long-term disease management.

Who Are The Primary Competitors In The Global Hemophilia B Gene Therapy Market?

Major companies operating in the hemophilia b gene therapy market are REGENXBIO Inc., Pfizer Inc., Bayer Aktiengesellschaft (Bayer AG), Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring LLC, Lonza Group AG, Alnylam Pharmaceuticals Inc., GenScript ProBio LLC, Ultragenyx Pharmaceutical Inc., Takara Bio Inc., Sangamo Therapeutics Inc., Precision BioSciences Inc., Synthego Corporation, MaxCyte Inc., uniQure N.V., Freeline Therapeutics Ltd., Be Biopharma Inc., Asklepios BioPharmaceutical Inc., Cellectis S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/hemophilia-b-gene-therapy-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Hemophilia B Gene Therapy Market?

North America was the largest region in the hemophilia b gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemophilia b gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Hemophilia B Gene Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33162&type=smp

Browse Through More Reports Similar to the Global Hemophilia B Gene Therapy Market 2026, By The Business Research Company

Hepatitis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Acquired Hemophilia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report

Hemophilia Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model